CD33 and acute myeloid leukemia: The first ADC approved by the US Food and Drug Administration (FDA), in 2000, was Mylotarg (gemtuzumab ozogamicin), a mAb to CD33 conjugated to a calicheamicin derivative for the treatment of CD33+ acute myeloid leukemia.